Legend Capital

Beijing DeepWise Science And Technology Co., Ltd. is a company that specializes in developing artificial intelligence-based medical application software aimed at enhancing clinical imaging analysis and diagnostics. Founded in 2017 and located in Beijing, China, DeepWise focuses on early screening and diagnosis of various malignant diseases, including lung and breast cancers. Its AI-driven software improves efficiency and diagnostic accuracy in healthcare, offering solutions to hospitals, medical centers, and imaging centers. The company's technology supports the online reading and consultation of medical images, leveraging big data in the cloud to facilitate timely and accurate disease detection and treatment.

Macrolux Medical is a medical technology company that specializes in endoscopic interventional solutions. It focuses on developing devices for both diagnosis and treatment across various medical fields, including urology, respiratory, and digestive health. By promoting these innovative solutions to a wide range of medical customers, Macrolux aims to enhance patient outcomes through earlier detection and improved treatment options. The company's commitment to advancing endoscopic therapy positions it as a key player in the medical device sector.

Macrolux Medical is a medical technology company that specializes in endoscopic interventional solutions. It focuses on developing devices for both diagnosis and treatment across various medical fields, including urology, respiratory, and digestive health. By promoting these innovative solutions to a wide range of medical customers, Macrolux aims to enhance patient outcomes through earlier detection and improved treatment options. The company's commitment to advancing endoscopic therapy positions it as a key player in the medical device sector.

Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments

HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.

BRC Biotechnology is a company focused on providing quality testing services for biopharmaceutical compliance. It supports the evaluation of biological agents and conducts quality assessments for various biopharmaceutical products, including cell and gene therapies, nucleic acid medications, and vaccines. Additionally, BRC Biotechnology is involved in research and development within the pharmaceutical sector, aiming to deliver innovative solutions and potential treatments for patients. The company's expertise extends to drug discovery and the development of diagnostic equipment, positioning it as a key player in the biotechnology industry.

Bio-Engine is a company based in Shanghai, China, focused on the research and development of veterinary biological products. Founded in 2014, Bio-Engine specializes in creating and producing antibodies, recombinant proteins, and vaccines for both humans and livestock using serum-free suspension culture technology for animal cells. The company's expertise extends to providing clinical trial services for pharmaceutical manufacturers and scientific research units.

Macrolux Medical is a medical technology company that specializes in endoscopic interventional solutions. It focuses on developing devices for both diagnosis and treatment across various medical fields, including urology, respiratory, and digestive health. By promoting these innovative solutions to a wide range of medical customers, Macrolux aims to enhance patient outcomes through earlier detection and improved treatment options. The company's commitment to advancing endoscopic therapy positions it as a key player in the medical device sector.

Nest is a manufacturer of laboratory equipment and consumables primarily focused on the life sciences sector. The company utilizes modern production tools in a large manufacturing facility to create various products, including cytology, microbial detection, and molecular biology consumables. In addition to these offerings, Nest also provides in vitro diagnostic and medical device-related products. By continually researching and developing new fundamental supplies, Nest aims to provide affordable solutions for its customers, ensuring that laboratories have access to essential consumables for their research needs.

Reliable Med is a medical device developer focused on creating and providing clinical mass spectrometry equipment for in vitro diagnostic (IVD) tests. The company addresses a significant need in the medical industry by offering high-end clinical mass spectrometry solutions and IVD detection kits. By enhancing diagnostic capabilities, Reliable Med aims to enable healthcare professionals to diagnose patients more efficiently and accurately.

Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

BioMap, founded in 2020 by Robin Li and Wei Liu, is an innovative life science AI company that has developed xTrimo, the largest protein-centric large language model platform. The company's technology enables scientists to model biological processes with greater accuracy, focusing on proteins and extending to system-level interactions. By leveraging limited data, BioMap facilitates the extraction of novel insights and predictions, addressing significant challenges in protein-related drug development. With a diverse team of over 300 experts, BioMap aims to enhance the effectiveness of new drugs, ultimately striving to improve patient outcomes in the healthcare sector.

Yeasen is a biotechnology company that provides molecular enzymes, proteins, antibodies, nucleic acids, and cells. They produce fields of life science research, diagnosis and detection, and biomedicine.

Reliable Med is a medical device developer focused on creating and providing clinical mass spectrometry equipment for in vitro diagnostic (IVD) tests. The company addresses a significant need in the medical industry by offering high-end clinical mass spectrometry solutions and IVD detection kits. By enhancing diagnostic capabilities, Reliable Med aims to enable healthcare professionals to diagnose patients more efficiently and accurately.

Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base, specializes in high-speed and high-precision radiology imaging solutions. With a significant research and development presence in Yonyou Industrial Park and a subsidiary in Chengdu, the company focuses on static computed tomography (CT), X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision developed China's first self-designed CMOS flat panel detector, known as the Merak series, which serves a diverse range of applications across medical, industrial, and security sectors. By providing advanced technological support both domestically and internationally, Nanovision aims to enhance imaging capabilities in various fields.

Beijing DeepWise Science And Technology Co., Ltd. is a company that specializes in developing artificial intelligence-based medical application software aimed at enhancing clinical imaging analysis and diagnostics. Founded in 2017 and located in Beijing, China, DeepWise focuses on early screening and diagnosis of various malignant diseases, including lung and breast cancers. Its AI-driven software improves efficiency and diagnostic accuracy in healthcare, offering solutions to hospitals, medical centers, and imaging centers. The company's technology supports the online reading and consultation of medical images, leveraging big data in the cloud to facilitate timely and accurate disease detection and treatment.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.

Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

China Diagnostic Medical Corporation is a diagnostic testing reagents maker.

Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its service offerings encompass clinical inspection instruments, various types of auxiliary reagents, technical support, management and certification, as well as the operation of independent medical laboratories. Chemclin is committed to introducing advanced diagnostic products and services to the Chinese market, thereby enhancing the capabilities of clinical diagnostics in the region.

Enjoy Dental Clinic is a prominent dental care provider established in 2007 and headquartered in Beijing, China. This large-scale dental chain integrates medical treatment with scientific research, education, and administrative functions. The clinic is committed to standardized practices for oral safety, utilizing a four-hand operation model and a rigorous "one person, one machine" aseptic disinfection protocol. Enjoy Dental Clinic employs advanced technologies, including 3D printing, digital-guided dental implants, ultra-thin cosmetic dentistry, and oral digital CT scanning, which enhance treatment efficacy and patient satisfaction. Additionally, the clinic offers franchising services, providing aspiring dentists with professional training and practical experience in clinic management.

Beijing DeepWise Science And Technology Co., Ltd. is a company that specializes in developing artificial intelligence-based medical application software aimed at enhancing clinical imaging analysis and diagnostics. Founded in 2017 and located in Beijing, China, DeepWise focuses on early screening and diagnosis of various malignant diseases, including lung and breast cancers. Its AI-driven software improves efficiency and diagnostic accuracy in healthcare, offering solutions to hospitals, medical centers, and imaging centers. The company's technology supports the online reading and consultation of medical images, leveraging big data in the cloud to facilitate timely and accurate disease detection and treatment.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Ayshealth Technology, founded in 2014 and based in Beijing, China, specializes in developing chronic disease management systems. The company offers a guideline-based decision support (GDS) platform that utilizes artificial intelligence technologies to assist healthcare providers in diagnosing and treating chronic diseases. This cloud-based service enables physicians, patients, hospital administrators, government agencies, and insurance companies to effectively monitor and manage health data related to chronic conditions. By providing data analytics and professional medical support, Ayshealth Technology enhances decision-making capabilities for doctors and facilitates comprehensive patient care.

Indi Molecular is a life sciences company based in Culver City, California, developing a fully synthetic class of diagnostic and therapeutic agents with antibody-like properties, known as protein-catalyzed capture agents (PCCs). PCCs are designed to replace traditional antibodies in in vivo imaging, therapeutics, and diagnostics, using a shared chelation chemistry platform that enables tailoring for therapeutic or PET imaging radionuclides. Produced via click chemistry, PCCs offer high selectivity, strong binding affinity, low molecular weight, and a fully synthetic composition compared with monoclonal antibodies. The company originated as a spinout from Integrated Diagnostics in 2013.

Shanghai Neuromedical Center is a specialized neurology clinic dedicated to advancing functional neurosurgery and providing comprehensive care in areas such as neurosurgery, neurology, neurorehabilitation, neuropsychology, and emergency critical care medicine. The center focuses on delivering expert treatment for conditions such as brain tumors and epilepsy, ensuring that patients receive high-quality, specialized care. By integrating clinical practice with scientific research and education, Shanghai Neuromedical Center aims to enhance patient outcomes and contribute to the evolution of neurosurgical techniques and methodologies.

Hisky Medical is a company based in Beijing, China, established in 2010, that specializes in the development, manufacturing, and marketing of medical equipment aimed at non-invasive liver diagnosis. The firm focuses on innovative technologies for disease diagnosis and has developed a product called FibroTouch, which is designed to facilitate the assessment of liver conditions without the need for invasive procedures. Through its advancements in medical technology, Hisky Medical aims to improve diagnostic accuracy and patient comfort in the evaluation of liver health.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.

Percans Oncology is a biotechnology company dedicated to advancing personalized cancer treatments. They specialize in developing individualized treatment plans by offering services such as cross-indication drug combination solutions, vitro susceptibility testing, and a tumor cell drug sensitivity detection kit. Their focus lies in creating innovative cancer-specific drug products centered around synthetic lethality and immunotherapy, aiming to enhance the effectiveness of each patient's treatment plan and extend lives.

MNCHIP is a developer and supplier of a comprehensive range of in vitro diagnostic (IVD) equipment aimed at enhancing clinical decision-making and treatment pathways. The company focuses on delivering high-quality medical devices at affordable prices, thereby ensuring accessibility for patients across different income levels. Among its current offerings are a chemistry analyzer and a PCR analyzer that utilize microfluidics technology, which improve the efficiency of IVD tests. Additionally, MNCHIP is preparing to launch an immunoassay analyzer and a hematology analyzer, further expanding its product line. By consistently bringing innovative solutions to market, MNCHIP plays a significant role in reducing healthcare spending while supporting healthcare professionals in their diagnostic efforts.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.

Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.

ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.